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Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worlwide and caused a
pandemic that is still ongoing. The virus can cause a disease named as COVID-19, which is composed of multi systemic manifestations
with a pulmonary system predominance. As the time passes, we are dealing more and more with a wide variety of effects and
complications of the disease in survivors as far as with concerns about the clinical outcome and the timeline of symptoms in different
patients. Since the lungs are the most involved organs and the post-COVID prolonged and persistent effects are mainly related to the
pulmonary system, it is crucial to define and predict the outcome and to determine the individuals that can progress to fibrosis and loss
of function of lungs. This review summarizes the current literature regarding the pulmonary complications in post-COVID syndrome
and the management of these conditions.
Key words: Post-COVID, pulmonary complications, multisystem inflammatory syndrome in adults (MIS-A)

1. Introduction
Our learning process about the COVID-19 disease, first
observed in Wuhan city of Hubei province of China since
the beginning of December 2019 and announced to the
world by the WHO China Office on 31 December 2019
and whose agent was identified on 7 January 2021, still
continues. The long-term effects and complications are
better understood day by day. After being discharged from
the hospital, some symptoms such as cough, exertional
dyspnea, muscle aches, and fatigue are observed,
sometimes lasting for months, especially in some of
the patients who have experienced severe COVID-19.
Chronic respiratory failure and permanent lung fibrosis
may develop in patients who have been intubated with
acute respiratory distress syndrome (ARDS) and received
invasive mechanical ventilation (IMV) therapy. Nonpulmonary systemic conditions such as diabetes mellitus,
neuromuscular problems, and cardiac pathologies are
also experienced. In this article, in the light of current
literature, long-term follow-up of COVID-19 patients and
the management of the problems observed in this process
will be reviewed in terms of post-COVID pulmonary
complications. Currently, the best known and most
common post-COVID syndrome (PCS) is pulmonary
involvement. In this section, this important issue will

be reviewed and discussed into six subsections, namely,
post-COVID periods and characteristics, post-COVID
syndrome definition pathogenesis from postacute COVID
to organ dysfunction, postconcussion symptoms (PCS)
clinical features, multisystem inflammatory syndrome in
adults (MIS-A), and lung complications management in
PCS.
2. Post-COVID periods and characteristics
2.1. COVID-19: clinical course and categorization
Siddiqi HK et al. proposed a 3-stage grading system for
the symptomatic disease of COVID-19 including the
increasing severity corresponding to different clinical
manifestations, response to treatment, and clinical course
[1]. Accordingly, the first stage (mild/early infection) is
characterized by mild nonspecific symptoms such as fever,
malaise and dry cough following infection and incubation.
The virus replicates mainly focused on the respiratory
system. At this stage, symptomatic treatment is essential.
Trial treatments with some antivirals have been applied to
prevent progression, reduce transmission, and accelerate
recovery. Most patients recover in this stage [1].
The second stage (moderate/pulmonary involvement
stage: stage IIa without hypoxia, stage IIb with hypoxia)
is characterized by viral pneumonia. The virus continues
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to replicate and settles in the lungs. Fever, cough,
hypoxia, radiological infiltrates, lymphopenia, and acute
inflammatory markers are elevated. Most patients at this
stage require hospitalization and treatment. Antivirals are
used for trial purposes. In the absence of hypoxia (Stage
IIa), corticosteroid use should be avoided. When hypoxia
develops (Stage IIb), corticosteroid and oxygen therapies
are provided [1].
Extrapulmonary
systemic
hyperinflammation
is observed in the third stage (severe/systemic
hyperinflammation stage) in a small number of patients.
IL-2, IL-6, IL-7, GCSF, macrophage inflammatory protein
1-alpha, TNF-alpha, CRP, ferritin, D-dimer are increased.
Troponin and pro-BNP may also be elevated. Shock,
vasoplegia, respiratory failure, cardiopulmonary collapse
may develop. Systemic involvements such as myocarditis
may occur. At this stage, immunomodulatory treatments
(corticosteroid, tocilizumab (IL-6 inhibitor) or anakinra
(IL-1 receptor antagonist), intravenous immune globulin)
are used to suppress systemic inflammation and prevent
multiorgan failure that may develop afterwards [1].
2.2. COVID-19 timeline
Patients become symptomatic 2–14 days after exposure
(mean time: day 5). It usually gets better in 7–10 days or
it starts to get worse 7 days after the onset of symptoms,
often at day 9–10. Intensive care unit (ICU) support
may be required and death usually occurs 14–28 days
after the onset of symptoms. In symptomatic, severe
cases, symptoms may last up to 6 months after recovery.
Permanent sequelae and pulmonary fibrosis may
develop in patients who have been treated in the ICU,
who have developed acute respiratory distress syndrome
(ARDS) and who have undergone IMV. Poor prognostic
factors reported in patients are as follows: advanced age,
comorbidities, smoking, obesity, genetic predisposition,
pregnancy, excessive increase in inflammatory markers,
lymphopenia, and treatment-resistant hypoxemia [2–6].
3. Post-COVID syndrome (PCS) definition
According to the definitions used in the NICE guideline
that includes the acute and chronic stages of the disease,
the symptoms are listed below:
Acute COVID-19: Presence of signs and symptoms of
COVID-19 from onset to 4 weeks. Ongoing symptomatic
COVID-19: Signs and symptoms of COVID-19 between 4
and 12 weeks.
Post-COVID-19: Signs and symptoms lasting more
than 12 weeks and not explained by an alternate diagnosis.
Long COVID-19: Refers to the association of both
ongoing and post-COVID-19 [7].
When diagnosing post-COVID-19 the following
criteria are taken into account: the patient’s symptoms
that started in the acute period persist, worsen, recur, or

3360

new symptoms develop; worsening, loss of quality of life
and functional status happens when compared to preCOVID-19 and the presence of permanent or progressive
radiological pathologies and abnormal laboratory findings
in the lungs [8].
However, there are many confounding situations
that make the definition of post-COVID-19 difficult.
It is not easy to define a timeline for acute and chronic
symptoms. It is also difficult to distinguish between postCOVID-19 and the previously known post-intensive care
(malnutrition, immobility, anxiety, etc.), post-ARDS,
post-mechanical ventilation (barotrauma, fibrosis,
pneumothorax, etc.) and post-intubation complications
(tracheal trauma, edema, stenosis, etc.). In order to
distinguish between previous comorbidities and the effects
of COVID-19, it is necessary to know the patient’s preCOVID-19 baseline status. It is important to distinguish
if the clinical outcome is due to post-COVID-19 or post
viral infection complications (bronchial hypersensitivity,
constitutional problems, etc.), or whether it is a postsecondary infection (resistant bacterial, fungal infections,
etc.). Problems after corticosteroid use (muscle weakness,
diabetes mellitus (DM), osteoporosis, infections, adrenal
suppression, etc.), post immunosuppression effects (antiIL-6/1), post traumatic syndrome (anxiety, panic, etc.),
post thrombotic (myocardial infarction (MI), stroke),
pulmonary embolism (PE), etc.), and post-ischemic
(infarction, functional limitation, etc.) conditions should
also be considered.
3.1. Frequency of postconcussion symptoms (PCS)
In a study in the USA, it was shown that only 6.75% of
COVID-19 patients returned to their previous health level
14–21 days after a positive test result [9]. Again, of the 233
cases of COVID-19 in the USA, most of which were mild
and only 8 patients were hospitalized, 43.4% were shown to
have symptoms lasting longer than 30 days, and 24.1% still
had at least one symptom after 90 days. When compared
to more severe COVID-19 cases, these rates were higher:
59.4% at 30 days and 40.6% at 90 days. In the acute period,
complications persisted for 30 days or longer in 14.3% of
even mild and asymptomatic cases [10]. It was revealed
that 87.4% of COVID-19 patients in Italy still complained
of at least one symptom 60 days after discharge [11].
Approximately 10%–20% of patients hospitalized with
the diagnosis of COVID-19 required rehospitalization
after discharge [12–13]. Of the 47,780 patients discharged
from hospital after acute COVID-19 in the UK, who were
followed-up at an average of 140 days, around a third of
individuals were readmitted (in total 14,060) and more
than 1 in 10 (in total 5875) died after discharge [14].
Patients at high risk of long-term complications were
treated in ICU or care units, received long-term highflow oxygen therapy (HFO), non-invasive mechanical
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ventilation (NIMV, CPAP, BIPAP) and were discharged on
oxygen therapy [15].
3.2. Importance of PCS
The rationale behind the long-term follow-up of patients
treated with a diagnosis of COVID-19 consists of
identification and monitorization of the early, medium, and
long-term respiratory complications; early detection and
treatment of life-limiting complications such as pulmonary
fibrosis and pulmonary vascular disease; assessment of
patients’ dyspnea, oxygen requirement, provision of
rehabilitation, palliative care, symptom management
and psychosocial support; ensure radiological resolution
of clinically recovered patients and identify and manage
previous undiagnosed respiratory disease. This detailed
evaluation is recommended to be done after every contact
with the patient to detect the complications in the early
period and manage permanent symptoms in the future
[15].
We still do not have clear information on the optimal
timing of the follow-up of these patients. The follow-up
period and intervals may vary from patient to patient.
Follow-up planning will change according to the
severity of the acute disease, the age of the patient, and
the accompanying diseases. Young, non-comorbid and
outpatient, mild patients who recover without treatment
or hospitalization may not require routine follow-up
unless they request. In patients who are elderly and have
comorbidities and moderate to severe disease but do not
require hospitalization should be given an appointment 3
weeks after the onset of the disease. In more severe cases
treated at the hospital, the first visit is recommended as
soon as within 1 week after discharge or 2–3 weeks at the
latest.
In the controls of the cases who have had the
COVID-19 disease, first of all, detailed anamnesis is taken
and physical examinations are performed in order to
determine the current symptoms and signs. Subsequently,
their COVID-19 disease histories (time of getting sick,
severity of the disease, treatments received, place and
duration of treatment, complications, etc.) are questioned.
Comorbid diseases, chronic medical conditions and the
treatments they are receiving are assessed. The range of
laboratory tests and imaging together with functional
measurements can be planned according to the clinical
findings. Appropriate medical treatments are arranged for
the existing symptoms or comorbid chronic conditions
and a plan is made for a regular follow-up. If worsening
of symptoms occurs, the patients should be recommended
to come earlier and not wait for the next visit. Education is
provided on possible symptoms after persistent COVID-19
and the need for rehabilitation is evaluated [8].
In the light of the information we have obtained from
the community-acquired pneumonia, patients diagnosed

with COVID-19 pneumonia will have a decrease in fever
in approximately 1 week. The complaints of chest pain and
sputum are expected to decrease in 4 weeks, and cough
and shortness of breath will be greatly reduced in 6 weeks.
Usually by 3 months, most of the symptoms will show
improvement, but fatigue can last up to 6 months and most
people return to their normal condition within 6 months
[7].
4. Pathogenesis from post-acute COVID to organ dysfunction
The respiratory system is the most severely affected system
during COVID-19 [16]. It is known that the disease, which
has a largely asymptomatic or minimally symptomatic
course, can be complicated by ARDS in the acute phase in
some cases and may require intensive care. Immediately
after the infection of the alveolar epithelium, thrombosis
characterized by alveolar wall damage, edema, hyaline
membranes, leukocyte infiltration and microangiopathic
changes predominates, while proinflammatory cytokine
release triggered by pattern recognition receptors and cell
damage, and an uncontrolled inflammatory process may
develop afterwards [17]. In addition to immune responses,
especially kinin-kallikrein system, renin-angiotensin
and coagulation system play an important role in the
worsening of the clinical outcome [18]. In patients with
ARDS, long periods of follow-up in the intensive care unit
and mechanical ventilation might be required.
After the first four-week period, recovery can be
achieved in most of the cases with severe disease, but
unfortunately, organ damage can become permanent
with prolonged symptoms, various pathologies and
chronic processes. These post-acute complications include
secondary infections, pulmonary function test disorders,
pulmonary thromboembolism, pulmonary hypertension,
and lung fibrosis [16].
Post-COVID secondary infections can change the
course of recovery [19]. It is suggested that a dysregulation
in immunological mechanisms develops and an
immunosuppressive state occurs during the control of
this response before it progresses to organ damage
especially following the hyperinflammatory acute period
that develops in COVID-19, which resembles the state
of immunosuppression that develops after sepsis [8].
However, although these secondary infections play a role
in complicating the clinical outcome, it is suggested that
they are not associated with permanent organ dysfunction
[20].
It has been reported that a decline in the measurements
obtained in pulmonary function tests develop after
COVID-19, which may continue for up to 12 months,
and may even become permanent especially in cases with
fibrosis or in relation to angiopathic changes [21–22]. It is
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stated that among the test variables, especially the decrease
in carbon monoxide diffusion capacity is more prominent,
which can be seen even in cases with normal lung volumes
and can be a result of vascular pathologies. Respiratory
muscle weakness, developing fibrosis, thrombosis and
angiopathies, especially the ones associated with underlying
diseases and intensive care follow-up processes, are some
risk factors for the decline of pulmonary function [22–23].
It is known that vascular microangiopathic processes,
micro and macro thrombosis are common from the
early stages of COVID-19, and this condition is more
common than in the other ARDS and viral infections
[20]. It is known that the damage, inflammation and
hypoxia that occurs during viral infection activates the
coagulation cascade, and this process results in platelet
activation with an increase in the level of mediators such
as von Willebrand factor and P-selectin, as well as direct
endothelial damage [24–26]. Increasing the complement
system activation with the addition of factors such as
antibody development may also contribute to the process
[27]. It is seen that this hypercoagulability may continue in
the post-acute period, and D-dimer levels, as an indicator
of ongoing fibrin formation and degradation, can give
an idea regarding this process. There are publications on
cases diagnosed with pulmonary embolism in the postacute and chronic period of infection [28–31]. Stasis,
endothelial damage and hypercoagulability, the classical
Virchow triad, might help understand the mechanism
[32]. It can be estimated that the cases whose mobilization
is impaired due to the ongoing disease state and symptoms
in the post-acute period are especially at high risk and
there is not enough information about when endothelial
damage heals. There are comments that thrombomodulin
levels can provide an information about the continuation
of the endothelial damage [24]. It has been reported
that inflammation continues in a prolonged period in
some of the cases, and a prolonged inflammation state
associated with IL-6 and Lipocalin-2 is observed [33–34].
It is suggested that hypercoagulability may be triggered
continuously, especially by ongoing inflammation, and
the antiphospholipid antibodies may also contribute to
this situation [35]. However, since it is already known
that transient antiphospholipid antibody positivity can be
observed after infections, information about the prolonged
period is far from certain, and further studies are needed
[36].
Unfortunately, one of the most serious complications
of the post-acute period is the development of fibrosis. It
has been reported that fibrosis can be detected from the
early period regardless of the pre-disease condition of the
lung and the severity of the disease [17,37]. TGF-b, which

is the most important factor in the healing process of the
developing parenchymal damage and during the regression
of inflammation, is thought to be the cytokine that plays
the most important role in the progression to fibrosis in
the post-COVID period [38–39]. The increase in TGF-b
level leads to a decrease in ACE-2 expression and increase
in Angiotensin-II levels that promotes proliferation
of fibroblasts, migration to tissue, transformation into
myofibroblasts, activation of myofibroblasts and ultimately
extracellular matrix accumulation [38]. Since it is known
that SARS-CoV-2, like other coronaviruses, increases
TGF-b levels with a direct viral effect [40], it is understood
that the development of fibrosis begins in the early stages,
becomes aggravated by changes in angiotensin levels, and
becomes evident during the resolution of inflammation.
It has been suggested that fibrotic processes are more
common especially in cases requiring mechanical
ventilation in the early period, and this may be related
to oxidative stress caused by high oxygen fractions and
trauma caused by positive airway pressure, and these
factors further facilitate the progression to fibrosis [38].
The radiological findings obtained in this study and
indicated in Figure 1 are as follows: Figures 1a, 1c, 1e,
and 1g show the radiological findings of a patient with
dyspnea at admission, whereas Figures 1b, 1d, 1f, and 1h
show the radiological improvement of the same lung slices
at 13 weeks post-COVID-19 after the patients received the
corticosteroid treatment. (From archives of Aydın Yılmaz)
5. PCS clinical features
Post-COVID-19 syndrome is defined as the duration of
symptoms and signs developing during or after COVID-19
infection for more than 12 weeks and exclusion of other
reasons to explain this clinical condition. Symptoms
and signs are manifested by frequently overlapping
clusters that can fluctuate over time, change, and affect
any system in the body [7]. Although the main route of
entry of SARS-CoV-2 to the body is the upper and lower
respiratory tract, it can cause diseases such as pneumonia,
acute lung damage and endotheliitis, pulmonary fibrosis
and thromboembolism in the long term, resulting in a
decrease in quality of life. Advanced age, the presence of
accompanying chronic diseases, and the severe course of
acute COVID-19 disease increase the risk of developing
post- COVID-19 syndrome1. It is estimated that 10%–35%
of COVID-19 patients who do not require hospitalization
develop post-covid symptoms regardless comorbidities,
whereas in hospitalized patients and patients with serious
illnesses this rate can be up to 80% [33]. Post-COVID
syndrome classification was made by different centers
according to initial symptoms, onset time and duration

Centers for Disease Control and Prevention. Post-COVID Conditions. Available from: https://www.cdc.gov/ coronavirus/2019-ncov/hcp/clinical-care
[Accessed 06/2021]
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Figure 1. a-c-e-g: Chest CT of the patient who presented with dyspnea at 13 weeks post-COVID-19. b-d-f-h: Significant regression in
CT findings of the patient are observed at the 25th week after steroid treatment. (From archives of Aydın Yılmaz)

of symptoms together with organ dysfunctions [41–43];
however, standardization of the classification is needed to
provide a common pathway for diagnostic and therapeutic,
as well as research purposes.
The most common pulmonary symptoms in postCOVID syndrome are shortness of breath and cough
[11, 44]. It has been reported that dyspnea and reduced
exercise tolerance develop in 10%–40% of the hospitalized
COVID-19 patients 2–4 months after discharge, and
shortness of breath develops in 65% of patients hospitalized
and discharged from the intensive care unit [45–46].
Commonly encountered clinical conditions are postCOVID interstitial lung disease (organized pneumonia,
pulmonary fibrosis), pulmonary embolism and chronic
cough, whereas cavitary lesions, small airway disease and
development of pulmonary hypertension are mentioned
as rare conditions.
5.1. Chronic cough and its management
Cough, which is among the initial symptoms of acute
COVID-19 disease, is a condition that is also frequently
encountered in post-COVID syndrome, along with
symptoms such as chronic fatigue, headache, and widespread
pain. The prevalence of cough was reported as 7%–10% in
two studies [47–48]. The reason of cough in some patients
is not clear. However, unlike cough that persists after a
cold or flu, chronic cough in post-COVID syndrome is
often accompanied by other multisystemic manifestations
that may indicate multifactorial pathogenesis or common
mechanisms underlying these symptoms. Cough may
result from invasion of vagal sensory neurons by SARS-

CoV-2, or from a neuroinflammatory response, or both,
and may lead to peripheral and central hypersensitivity in
the cough pathways [49]. After the differential diagnosis
of chronic cough is made (according to the guidelines),
treatment can be started. However, although guidelines
serve as a reference for current approaches to acute
and chronic cough, the optimal management of cough
associated with COVID-19 remains unclear.
In the NICE guideline, opioid-derived antitussives
are recommended in acute COVID, but attention
should be paid to their addictive potential and central
nervous system side effects [7]. Oral or inhaled steroids
can be given to asthmatic patients. Chronic refractory
or unexplained cough in post-COVID syndrome may
result from neuroinflammation leading to larynx and
tracheal hypersensitivity. Neuromodulator agents such
as gabapentin and pregabalin can be recommended.
Antimuscarinic drugs such as tiotropium can be
used to control COVID-19 cough as they can reduce
cough sensitivity in acute viral upper respiratory tract
infection. Speech and language therapy offered as part
of a multimodal therapy in synergy with other aspects of
pulmonary rehabilitation can help patients recover from
post-COVID syndrome [49].
Studies are needed to provide insights into the
epidemiology of post-COVID chronic cough and its
impact on quality of life as well as cough hypersensitivity.
5.2. Cavitary lesions and management
The radiological specific findings of COVID-19 disease are
unilateral/bilateral ground-glass opacities with peripheral
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distribution, fine reticular opacities, and vascular
thickening [50]. The cavity is an air-filled space formed
within the area of pulmonary

consolidation, mass, or
nodule as a result of liquefaction of the necrotic portion of
the lesion and evacuation of this necrotic material through
the bronchial tree. It is rare for viral pneumonias (including
SARS-CoV and MERS-CoV) to cause pulmonary
cavitation even in severe and advanced viral infection
[51]. However, cavitary lesions have been published as case
series in the prolonged symptomatic period (4–12 weeks)
in COVID-19 disease. In a series of 12 cases (1.7%) within
the 689 COVID-19 pneumonia patient group reported by
Zoumot Z et al., the mean time from the first symptom
onset to the detection of cavitation was 36 (21–54) days,
and all patients had bilateral peripheral ground glass
opacities on their first chest tomography. Consolidation
and air bronchograms were detected in most of the
patients and cobblestone appearance with interlobular
septal thickenings in half of them [52]. Tocilizumab
and steroid therapy, which cause immunosuppression,
were administered to patients followed up in the
intensive care unit with severe COVID-19 pneumonia,
but bacterial agents that could cause cavitary lesions
were detected in only 4 patients. While simultaneous
hemoptysis and pneumothorax developed in 2 patients,
a total of 4 patients had in addition radiological findings
compatible with invasive aspergillosis. The authors
describe the development of cavitation in these patients
as a result of multifactorial reasons such as: bacterial
and fungal coinfection, immunosuppressive effects of
glucocorticosteroids and tocilizumab, inflammatory
pathways specific to SARS-CoV-2, susceptibility to
COVID-19 related venous thromboembolism and microinfarctions or infarctions causing cavitary lesions. They
also emphasized that the natural course of these cavities in
survivors is uncertain [52].
Tuberculosis disease, which is endemic in our country
and usually presents with a cavity, has also been reported
in several publications as a co-infection with COVID-19.
Both diseases have common risk factors such as underlying
comorbidities (diabetes, immunosuppression) and low
socio-economic status, air pollution, living in crowded
environments, and both of them are important infectious
pathogens that continue to threaten the world population.
Presence of active or previous history of tuberculosis
has been found to be associated with the development
of COVID-19 and might worsen the prognosis of acute
infection [53].
It has been found that proinflammatory cytokines
such as TNF-α, IL-6, IL-10, IL-1β and chemokines
increase in COVID-19 patients (18). Increasing IL-10, Th1
suppression, and suppression of IL-6 level by tocilizumab
used during the cytokine storm period increase the risk
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of invasive pulmonary aspergillosis, which progresses with
a cavity and has a very poor prognosis in the follow-up
period in COVID-19 patients [54–55].
Although there is no standard diagnosis or treatment
algorithm in the management of cavitary lesions, which we
encounter mostly in the prolonged symptomatic period in
post-COVID syndrome, attention should be paid to fungal
infections especially aspergillosis, tuberculosis, differential
laboratory, and microbiological examinations should
be performed and the appropriate treatment should be
started as soon as possible.
Below, in Figure 2a the CT findings of a patient
presenting with a cavitary lesion are shown, and Figure
2b shows the remaining changes in lungs after antibiotic
treatment. (From archives of Aydın Yılmaz)
5.3. Small airway disease and its management
The development of small airway disease (SAD) in postCOVID syndrome is a very new clinical condition. A
study, which is still in the publication stage and included
100 patients, tried to show if there is a correlation between
air trapping measured with quantitative thorax computed
tomography (CT) and pulmonary function test [56].
Although it is difficult to define small airways on CT,
studies have found that air trapping detected on CT can
be a biomarker of functional SAD [57]. In this study, it was
stated that SARS-CoV-2 infection itself causes functional
SAD and air trapping, whereas restrictive lung disease and
deterioration in gas exchange are caused by lung damage
and ARDS, regardless of the underlying cause.
The underlying mechanism is explained as follows:
The angiotensin-converting enzyme 2 (ACE2) receptor,
which facilitates SARS-CoV-2 entry in cells, is expressed
throughout the airway, including the small airways.
Therefore, the functional SAD observed in patients in the
post-COVID syndrome may result from direct infection
of the small airways by SARS-CoV-2, even in patients with
mild acute infection. In this case, post-COVID SAD may
result from an ongoing damage-repair process, cellular
debris, and/or abnormal mucus production. Conversely,
the immune response induced by SARS-CoV-2 can
directly induce post-COVID SAD even in the absence
of infection. Regardless of the underlying mechanism,
the development of functional SAD months after acute
infection is of concern for airway remodeling and fibrosis.
In one study, no correlation was observed between
pulmonary function tests, quantitative CT measurements
of ground glass opacities, air trapping and the period
time from diagnosis. The median time from diagnosis to
pulmonary function measurements and chest CT imaging
was approximately 75 days. Multicenter, prospective
studies are needed for the frequency of SAD and treatment
recommendations in post-COVID syndrome.
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A

B

Figure 2. a: Chest CT of the patient who presented with a cavity in the left upper lobe at 12 weeks post-COVID. b: CT showed a
regression of the cavity after 6 weeks of antibiotic treatment. (From archives of Aydın Yılmaz)

Below, in Figure 3a, diffusion capacity and pulmonary
function tests of a patient at admission, and, in Figure
3b, the improvement of these tests values after receiving
corticosteroid treatment are shown. (From archives of
Aydın Yılmaz)
5.4. Pulmonary hypertension and its management
Although the exact mechanism is not known in some
viral infections such as HIV, the frequency of pulmonary
arterial hypertension (PAH) has increased [58]. In the
COVID-19 disease, the pulmonary artery wall thickness
increased twice as compared to the H1N1-infected
individuals as showed in autopsies. Pulmonary vascular
thickening in COVID-19 is thought to have a vital role in
the development of acute respiratory failure, and based
on this result, we can think that patients recovering from
COVID-19 may be prone to develop PAH and right heart
failure [59–60].
6. COVID-19 and multisystem inflammatory syndrome
in adults (MIS-A)
Multisystem inflammatory syndrome (MIS) is a finding
that is observed in the prolonged course of COVID-19
but is not very common according to the available data.
This syndrome, which was stated to affect children for
the first time in articles published in March 2020 in
England and the USA, was named as MIS-C (child)
[61–63]. Shortly after MIS-C was defined (June 2020), a
clinical picture compatible with MIS was reported also in
adults and was defined as MIS-A(adult) [64–66]. Among
the inflammatory syndromes secondary to COVID-19,
Kawasaki-like syndrome has also been reported especially
in children. Case reports that describe Kawasaki-like
syndrome in adults are also available in the literature

[67]. Most et al. also mention about the myocarditis-like
syndrome in adults as another post-COVID inflammatory
syndrome in their review [68]. A detailed Venn diagram
of the overlap of symptoms and signs of Kawasaki disease,
MIS, and acute cardiovascular syndrome is included
in another part of this review. Here, only MIS-A will be
discussed in details.
Cardiovascular,
gastrointestinal,
dermatological
and neurological symptoms without serious respiratory
disorders are reported in the first published cases with
the diagnosis of MIS-A. In the course of MIS-A, diagnosis
is challenging due to the heterogeneity of symptoms and
findings. SARS-CoV-2 PCR or antigen test positivity may
not be detected in the diagnosis of MIS-A, and antibody
test positivity may be the only evidence that the case has
COVID-19 disease [69].
The pathogenesis of the relationship between acute
COVID-19 disease and MIS-A is not clearly understood,
thus making it difficult to prevent the unwanted
complications such as MIS-A. According to the data
obtained from published case reports, the definition of
MIS-A is made by the following five criteria [69]:
1. Presence of severe disease requiring hospitalization
in an individual >21 years of age, 2. positive test result
of SARS-CoV-2 infection (nucleic acid, antigen or
antibody); 3. presence of severe dysfunction in one or
more extrapulmonary organs/systems (hypotension or
shock, cardiac dysfunction, arterial or venous thrombosis,
acute liver injury), 4. elevated inflammatory parameters
(CRP, ferritin, D-dimer or IL-6), 5. no serious respiratory
problems (organ dysfunctions not associated with tissue
hypoxia). MIS-A cannot be excluded in the presence of
mild respiratory symptoms.
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Figure 3. Diffusion and pulmonary function test findings of the patient above at first admission (a) and after steroid treatment (b).
(From archives of Aydın Yılmaz)

As of May 2021, as of the time of writing this article,
the number of full-text articles accessed with the keyword
“MIS-A and COVID-19” in the PubMed index was
determined as 186. All of these articles were case series.
These numbers indicate that MIS-A has been seen or
reported relatively less, when compared to the numerous
articles on COVID-19 published since the beginning of the
pandemic.
Although hyperinflammation and extrapulmonary
organ dysfunction are common in hospitalized adults
with severe COVID-19, respiratory failure is often
present in these severe cases. In MIS-A, there may be
only mild respiratory symptoms, mild hypoxemia or rare
radiological abnormalities. Although the pathophysiology
of MIS is not fully known, it suggests that multi-organ/
system involvement such as heart, brain, liver, kidney and
gastrointestinal involvement is associated with endothelial
damage, thromboinflammation, dysregulated immune
responses, and renin-angiotensin-aldosterone system
dysregulation [69].
The interval between COVID-19 infection and the
development of MIS-A is not known. It may be a prolonged
clinical manifestation of an acute infection or a postacute
phenomenon. Dyspnea may become prominent on days 5–8
of the Covid-19 infection, whereas the critical illness occurs
usually 10–12 days after symptom onset. On the other hand,
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MIS-A is reported usually within 2–5 weeks after infection.
In their review, Vogel et al. defined cases according
to the levels of diagnostic certainty within four different
groups as definitive, probable, possible case and case with
insufficient evidence for MIS-C/A. This classification is a
useful definition as it includes demographics, symptoms,
signs and laboratory results [70].
Level 1: Definitive case
Age < 21 years (MIS-C) and ≥21 years (MIS-A); fever
for ≥3 consecutive days; the presence of two or more of
the following clinical features: mucocutaneous findings,
gastrointestinal symptoms, shock/hypotension, neurological
findings; elevation in any of inflammatory markers (CRP,
ESR, ferritin or procalcitonin); the presence of two or more
of disease activity markers: increased BNP or NT-pro BNP or
troponin, neutrophilia, lymphopenia or thrombocytopenia,
detection of cardiac involvement by echocardiography, EKG
changes consistent with myocarditis or myo-pericarditis
and the confirmation of active SARS-CoV-2 infection by
laboratory or having a history of confirmed COVID-19 in
the past 12 weeks or a history of close contact with a known
case of COVID-19 in the last 12 weeks or a recent SARSCoV-2 vaccination history.
Level 2: Probable case
Level 2a: Same criteria as Level 1, except for disease
activity measurements; a history of known or strongly
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suspected COVID-19 in the last 12 weeks or a close contact
with a known or strongly suspected COVID-19 case in the
last 12 weeks or a recent SARS-CoV-2 vaccination.
Level 2b: Presence of the same criteria as Level 1 except
fever that has lasted for 1–2 days or that can be subjective.
Level 3: Possible case
Level 3a: Age < 21 years (MIS-C) and ≥21 years (MIS-A);
fever for >3 consecutive days; two or more of the following
clinical features: mucocutaneous, gastrointestinal, shock/
hypotension, neurological, physical examination findings
of heart failure: gallop rhythm or rales, lower extremity
edema, jugular venous engorgement, hepatosplenomegaly;
absence of elevated inflammatory markers and a history
of known or strongly suspected COVID-19 in the last 12
weeks or close contact with a known or strongly suspected
COVID-19 case in the last 12 weeks or a recent SARSCoV-2 vaccination.
Level 3b: Presence of the same criteria as Level 2a except
fever that lasted for 1–2 days and that can be subjective.
Level 4: Insufficient evidence
A case that does not fully meet the case definitions in
levels 1–3.
The treatment for MIS-A is supportive, but there
may also be a need for intensive care. The current
protocol includes biological agents such as intravenous
immunoglobulin (IVIG), corticosteroids, tocilizumab,
anakinra or infliximab. It is reported that the treatment
response is rapid, and the patient can improve
dramatically within days. However, it may also result
in unresponsiveness to treatment and death [71]. It is
important for the clinician to notice the early findings
and approach them in a proper way. Because it is a clinical
condition that can be overlooked and antibody tests are
not widely used yet, a careful and systematic approach
is required for the diagnosis of MIS-A, with a good
collaboration of multidisciplinary specialists.
7. PCS lung complications management
As more than one year has passed since the pandemics of
SARS-CoV-2 started, we gained knowledge about the longterm pulmonary complications of COVID-19 disease.
Experience with longer follow-ups will further shape the
approach to PCS patients. Viral pneumonia is the most
common and the most severe problem in the course of the
disease. It is not yet clear whether disseminated COVID-19
pneumonia can have long-term effects resulting in
persistent fibrosis in the lungs. The number of studies and
reviews written on post-COVID pulmonary fibrosis is
increasing day by day. Post-COVID pulmonary fibrosis is
referred to as Post-COVID interstitial lung disease (PCILD) in most articles. In this article, the abbreviation PC-

ILD will be used. In an article published from India in
March 2021, PC-ILD was defined as ‘the tsunami that will
follow the earthquake’ [38,72–73]. Although it is reported
that there are three possible different clinical courses, the
frequency of each is not known. According to this review,
most lung involvements heal without sequelae, some
heal with minimal fibrosis without worsening, and a few
progress to advanced fibrosis that requires antifibrotic
treatment. Advanced age, severe pneumonia, prolonged
ICU stay and prolonged MV duration, smoking and
chronic alcoholism history are some of the predictors for
PC-ILD development. High CRP, IL-6 and LDH levels
in the acute phase may lead to activation of fibroblast
proliferation in the repair process of lung injury [72,73].
7.1. PC-ILD prevention and treatment
In order to minimize the risk factors for PC-ILD
development shortening the length of stay in the intensive
care unit, avoiding invasive mechanical ventilation support
if possible, managing the case with low airway pressure in
case of forced MV, proper management of concomitant
diseases and prevention of bacterial superinfections are
some of the measures that can be taken.
Treatment options can be listed as follows based on the
available evidence [74]:
Antivirals: The close relationship between the
development of lung fibrosis and high viral load is
known, and the effectiveness of early antiviral treatments
(remdesivir, favipiravir) to reduce viral load has been
shown in some studies [74]. The necessity of effective
antivirals in pandemic control is indisputable. However,
there is no specific antiviral agent developed for the SARSCoV-2 agent yet and many studies are ongoing in order to
develop effective drugs.
Anti-inflammatory drugs: The efficacy of systemic
steroids has been proven in the treatment of severe disease
in the acute period.2 However, there is insufficient evidence
for long-term use in the prevention of PC-ILD. There are
studies suggesting that 20–30 mg/day prednisolone should
be started in the presence of diffuse ground glass opacities
in the prevention of lung fibrosis and continued until
radiological improvement is achieved [74].
Antifibrotics: As mentioned above, lung involvement
should be monitored for up to 3 months in the postCOVID period, and it should be kept in mind that there
may be a possibility for regression. In other words, it is
not necessary to rush for the antifibrotic treatment. If
fibrosis still persists at the end of the 12th week, there is a
rationale for the use of these agents in the treatment of PCILD, although there is not enough data yet. Pirfenidone or
nintedanib should be used for at least 1–3 months for a
clear measurement of the antifibrotic response. In addition

World Health Organization (WHO). Corticosteroids for COVID-19. Available from:https://www.who.int/publications/item/WHO-2019-nCoVCorticosteroids-2020 [Accessed 06/2021].
2

3367

ESENDAĞLI et al. / Turk J Med Sci

Figure 4. a-b-c: Chest CT of the patient who applied with diffuse chest pain and low oxygen saturation at 8 weeks post-COVID: bilateral
pulmonary embolism. (From archives of Aydın Yılmaz.

to clinical findings, response to antifibrotics should be
evaluated objectively with HRCT, DLCO and 6MWT [75].
Concomitant use of steroids and antifibrotics is also being
tried, and the long-term results are not yet known.
Pulmonary rehabilitation (PR): PR is a vital treatment
approach that can also be applied at home. Since PC-ILD
may also cause hypoxemia, long-term use of oxygen and
PR at home can help in recovery [7].
Other supportive treatments: Anticoagulation,
psychiatric support, family support, pneumococcal and
influenza vaccinations are required until the patient is
fully mobile, and evaluation of progressive and persistent
PC-ILD for lung transplantation in selected cases is
recommended [7].
7.2. Pulmonary embolism prevention and treatment
After the acute phase of the disease, the state of
hypercoagulation may last for a long time, so long-term
prophylaxis may be recommended in cases with severe
disease. However, this issue is not very clear yet. In
cases with severe disease and accompanying pulmonary
embolism, anticoagulation administration is required
according to the recommendations by the specific
guidelines. It is recommended to evaluate the patient for
the development of pulmonary hypertension (PHT) at the
end of 12 weeks, and to discontinue the treatment at the
end of the 3rd month if PHT has not developed. Lastly,
the measurement and follow-up of D-Dimer level, which
is also an acute phase reactant and is not specific for

COVID-19, for chronic embolism is controversial [74].3
CT findings of a patient presenting with bilateral
pulmonary embolism are shown in Figure 4. Figure 4a
shows a centrally located thrombus on the right pulmonary
artery, whereas Figure 4b and 4c show the presence of
thrombus in segmental branches of the left and right
pulmonary arteries, respectively. (From archives of Aydın
Yılmaz)
8. Conclusion
COVID-19 disease is not just an acute infection, but
is a complex entity with post-infection complications
and long effects especially involving the pulmonary
system, which emphasizes the fact that the treatment of
this disease continues even after the patients have been
discharged. Further detailed studies are needed in order
to identify biomarkers and risk factors for the individuals
that can progress, thus enabling a prompt intervention and
treatment to minimize the long term effects. There are still
many unknowns regarding the pathophysiology of this
new disease, which makes the approach to these patients
difficult for the moment and COVID-19 specialized
hospitals or centers might help for an optimized treatment
and follow-up.
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